BPA CALL
ActiveHT941026FE110
Department of Defense › Defense Health Agency › DEFENSE HEALTH AGENCY HCD WEST
$205.8K
obligated · signed 4 months ago
BPA FOR PLUVICTO AND LUTATHERA INJECTION
Performance timeline
Start
Jul 21, 2026
End
Apr 30, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Apr 30, 2027
NOVARTIS PHARMACEUTICALS CORPORATION
Contract HT941026FE110
UEI
NG61ZA8TADW3
Parent Company
NOVARTIS SANIERUNGSSTIFTUNG
Capabilities & Certifications
Headquarters Location
Congressional District: 11
Current Obligation
$205,766
Base + Exercised Options
$205,766
Total Ceiling Value
$205,766
Contract Type
FIRM FIXED PRICE
NAICS
PHARMACEUTICAL PREPARATION MANUFACTURING
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 11
Awarding Agency
Top-tier agency
Defense Health Agency
Sub-tier agency
DEFENSE HEALTH AGENCY HCD WEST
Office
Funding Agency
Top-tier agency
Defense Health Agency
Sub-tier agency
NAV MED CTR SAN DIEGO CA - MM
Office
Contract Vehicle
HT941026AE002
BPADepartment of Defense
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.